Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 8/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.45 |
| ▸ | ESR1 | P03372 | 5/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945808 | 0.90 | S1PR1 (0.57) | S1PR1S1PR3ESR1ESR2AKR1C3 | |
| SCHEMBL2950814 | 0.84 | S1PR1 (0.54) | S1PR1S1PR3ESR1ESR2PDE3B | |
| SCHEMBL2948106 | 0.81 | S1PR1 (0.52) | S1PR1S1PR3ESR1ESR2AKR1C3 | |
| SCHEMBL5681860 | 0.80 | ESR1 (0.64) | ESR1ESR2 | |
| SCHEMBL2948825 | 0.79 | APP (0.55) | S1PR1S1PR3 | |
| SCHEMBL4637120 | 0.79 | AKR1C3 (0.51) | S1PR1S1PR3ESR2AKR1C3AKR1C2 | |
| SCHEMBL20040602 | 0.79 | CYP11B2 (0.50) | ESR1ESR2 | |
| SCHEMBL27638536 | 0.77 | AKR1C3 (0.55) | S1PR1S1PR3AKR1C3AKR1C2PDE3B | |
| SCHEMBL13233711 | 0.77 | S1PR1 (0.54) | S1PR1S1PR3 | |
| SCHEMBL27638539 | 0.76 | AR (0.59) | S1PR1S1PR3AKR1C3AKR1C2PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750021-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2010-07-06 | — | — | US | disclosed |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-05-21 | — | — | US | disclosed |
| US-7417065-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2008-08-26 | — | — | US | disclosed |
| EP-1628967-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2006-03-01 | — | — | EP | disclosed |
| US-20050014725-A1 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2005-01-20 | — | — | US | disclosed |
| WO-2005000833-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014725-A1 | Immunosuppressant compounds and compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885ESR1 819/4885 |
| US-20090131400-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885ESR1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.